Information from one maternal-infant pair with ivacaftor and lumacaftor indicates that maternal ivacaftor therapy produce low levels in milk. An international survey of cystic fibrosis centers found no adverse effects in breastfed infants of mothers taking these drugs. A task force respiratory experts from Europe, Australia and New Zealand found that these drugs are probably safe during breastfeeding.[1] One breastfed infant had transient elevations in bilirubin and liver enzymes during maternal therapy that could not definitively be attributed to the drugs in breastmilk. Until more data are available, monitoring of infant bilirubin and liver enzymes might be advisable during breastfeeding with maternal lumacaftor and ivacaftor therapy.[2] Congenital cataracts in breastfed infants has been reported in the infants of mothers who took ivacaftor during pregnancy. Examination of breastfed infants for cataracts has been recommended.[3] Anecdotal evidence indicates that the drugs in breastmilk may moderate cystic fibrosis in breastfed infants.
来自一对接受依伐卡托和鲁马卡托治疗的母婴的信息表明，母亲使用依伐卡托治疗时，母乳中的药物水平较低。一项对囊性纤维化中心的国际调查发现，服用这些药物的母亲所哺乳的婴儿未出现不良反应。一个由欧洲、澳大利亚和新西兰的呼吸专家组成的特别工作组发现，这些药物在母乳喂养期间可能是安全的。[1]一名母乳喂养的婴儿在母亲治疗期间胆红素和肝酶出现短暂升高，但无法明确归因于母乳中的药物。在获得更多数据之前，在母亲使用鲁马卡托和依伐卡托治疗进行母乳喂养期间，监测婴儿的胆红素和肝酶可能是可取的。[2]有报道称，在孕期服用依伐卡托的母亲所哺乳的婴儿中出现了先天性白内障。已建议对母乳喂养的婴儿进行白内障检查。[3]轶事证据表明，母乳中的药物可能会减轻母乳喂养婴儿的囊性纤维化症状。
